Study overview
The RESTORE study is a randomized, double-blind, placebo-controlled trial for individuals 18-75 years old with chronic tetraplegia due to traumatic, cervical spinal cord injury (SCI). Participants will perform daily subcutaneous injections of NVG-291 for 12 weeks, followed by 4 weeks of observation. Learn more about the study with NervGen Pharma Corp.
Study eligibility
To take part in this study, participants must:
- Be aged 18–75
- Have chronic tetraplegia due to traumatic SCI (≥C7; ASIA Impairment Scale C or D)
- Are 1-10 years post injury
